ArticleNMR in biomedicine2025
Automatic Identification of Potential Cellular Metabolites for Untargeted NMR Metabolomics.
Article in NMR in biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Analysis of serum NMR metabolomics in fibrotic diseases of the myocardium.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Metabolomic Relationships Between Lung Cancer and Alzheimer's Disease Using Serum Nuclear Magnetic Resonance Spectroscopy.NMR in biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
An organism's metabolic profile provides vital information pertaining to its physiology or pathology. To monitor these biochemical changes, Nuclear Magnetic Resonance (NMR) spectroscopy has found success in non-invasively observing metabolite changes within intact samples in an untargeted manner. However, biological samples are chemically complex, comprised of many different constituents (amino acids, carbohydrates, and lipids) at varying concentrations depending on physiological and pathological conditions. Due to the narrow spectral window of proton NMR, compound resonance frequencies can often overlap, making the identification and monitoring of metabolites difficult and time consuming, particularly when dealing with large numbers of samples. Here, we introduce a Python program (ROIAL-NMR) to systematically identify potential metabolites from defined proton NMR spectral regions-of-interest (ROIs), which are identified from complex biological samples (i.e., human serum, saliva, sweat, urine, CSF, and tissues) using the Human Metabolome Database (HMDB) as a reference platform. Briefly, for disease-versus-control studies, the program considers disease types and utilizes study-defined ROIs together with their differing intensity levels, according to sample types, in differentiating disease from control to propose potential metabolites represented by these ROIs in an output table. In this report, we illustrate the utility of the program with one of our recent studies, where we measured proton NMR spectra of serum samples taken from lung cancer (LC) patients, with and without Alzheimer's disease and related dementia (ADRD). The program successfully identified 88 metabolites, with 66 differentiating LC from control patients, and 80 distinguishing LC patients with ADRD from those without ADRD to provide important information regarding pathophysiology in complex biological samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.